Regulation of the pentose phosphate pathway in cancer

doi:10.1007/s13238-014-0082-8

Protein Cell

2014, Vol. 5

Issue (8) : 592-602 https://doi.org/10.1007/s13238-014-0082-8

REVIEW

Regulation of the pentose phosphate pathway in cancer

Peng Jiang^1,^*(

),Wenjing Du³,Mian Wu^2,^*(

)

1. School of Life Sciences, Tsinghua University, Beijing 100084, China
2. Hefei National Laboratory for Physical Sciences at Microscale, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, China
3. Department of Cancer Biology, Perelman School of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104, USA

Download: PDF(395 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Energy metabolism is significantly reprogrammed in many human cancers, and these alterations confer many advantages to cancer cells, including the promotion of biosynthesis, ATP generation, detoxification and support of rapid proliferation. The pentose phosphate pathway (PPP) is a major pathway for glucose catabolism. The PPP directs glucose flux to its oxidative branch and produces a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), an essential reductant in anabolic processes. It has become clear that the PPP plays a critical role in regulating cancer cell growth by supplying cells with not only ribose-5-phosphate but also NADPH for detoxification of intracellular reactive oxygen species, reductive biosynthesis and ribose biogenesis. Thus, alteration of the PPP contributes directly to cell proliferation, survival and senescence. Furthermore, recent studies have shown that the PPP is regulated oncogenically and/or metabolically by numerous factors, including tumor suppressors, oncoproteins and intracellular metabolites. Dysregulation of PPP flux dramatically impacts cancer growth and survival. Therefore, a better understanding of how the PPP is reprogrammed and the mechanism underlying the balance between glycolysis and PPP flux in cancer will be valuable in developing therapeutic strategies targeting this pathway.

Keywords pentose phosphate pathway (PPP) G6PD NADPH glucose metabolism cancer cell Proliferation

Corresponding Author(s): Peng Jiang

Issue Date: 27 August 2014

Cite this article:

Peng Jiang,Wenjing Du,Mian Wu. Regulation of the pentose phosphate pathway in cancer[J]. Protein Cell, 2014, 5(8): 592-602.

URL:

https://academic.hep.com.cn/pac/EN/10.1007/s13238-014-0082-8
https://academic.hep.com.cn/pac/EN/Y2014/V5/I8/592

1	Amelio I, Markert EK, Ruflni A, Antonov AV, Sayan BS, Tucci P, Agostini M, Mineo TC, Levine AJ, Melino G(2013) p73 regulates serine biosynthesis in cancer. Oncogene doi: 10.1038/onc.2013.456
2	Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science334: 1278-1283 doi: 10.1126/science.1211485
3	Bader AG, Kang S, Zhao L, Vogt PK(2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer5: 921-929 doi: 10.1038/nrc1753
4	Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH(2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell126: 107-120 doi: 10.1016/j.cell.2006.05.036
5	Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH(2013) Metabolic regulation by p53 family members. Cell Metab18: 617-633 doi: 10.1016/j.cmet.2013.06.019
6	Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A (2010) The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol119: 487-494 doi: 10.1007/s00401-010-0645-6
7	Bonneau D, Longy M(2000) Mutations of the human PTEN gene. Hum Mutat16: 109-122 doi: 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0
8	Cairns RA, Harris IS, Mak TW(2011) Regulation of cancer cell metabolism. Nat Rev Cancer11: 85-95 doi: 10.1038/nrc2981
9	Candi E, Agostini M, Melino G, Bernassola F(2014) How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum Mutat35: 702-714 doi: 10.1002/humu.22523
10	Cantley LC(2002) The phosphoinositide 3-kinase pathway. Science296: 1655-1657 doi: 10.1126/science.296.5573.1655
11	Cantley LC, Neel BG(1999) Newinsights into tumor suppression:PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA96: 4240-4245 doi: 10.1073/pnas.96.8.4240
12	Cheung EC, Athineos D, Lee P, Ridgway RA, Lambie W, Nixon C, Strathdee D, Blyth K, Sansom OJ, Vousden KH(2013) TIGAR is required for efflcient intestinal regeneration and tumorigenesis. Dev Cell25: 463-477 doi: 10.1016/j.devcel.2013.05.001
13	Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A (2009) Mutations of multiple genes cause deregulation of NfkappaB in diffuse large B-cell lymphoma. Nature459: 717-721 doi: 10.1038/nature07968
14	Cosentino C, Grieco D, Costanzo V(2011) ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J30: 546-555 doi: 10.1038/emboj.2010.330
15	Costa Rosa LF, Curi R, Murphy C, Newsholme P(1995) Effect of adrenaline and phorbol myristate acetate or bacterial lipopolysaccharide on stimulation of pathways of macrophage glucose, glutamine and O2 metabolism. Evidence for cyclic AMP-dependent protein kinase mediated inhibition of glucose-6-phosphate dehydrogenase and activation of NADP+-dependent ‘malic’ enzyme. Biochem J310(Pt 2): 709-714
16	da Silva CG, Jarzyna R, Specht A, Kaczmarek E(2006) Extracellular nucleotides and adenosine independently activate AMPactivated protein kinase in endothelial cells: involvement of P2 receptors and adenosine transporters. Circ Res98: e39-e47 doi: 10.1161/01.RES.0000215436.92414.1d
17	Dang CV(2012) MYC on the path to cancer. Cell149: 22-35 doi: 10.1016/j.cell.2012.03.003
18	Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC (2010) Cancerassociated IDH1 mutations produce 2-hydroxyglutarate. Nature465: 966 doi: 10.1038/nature09132
19	DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB(2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab7: 11-20 doi: 10.1016/j.cmet.2007.10.002
20	Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M, Yang X(2013) TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol15: 991-1000 doi: 10.1038/ncb2789
21	Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell39: 171-183 doi: 10.1016/j.molcel.2010.06.022
22	Engelman JA(2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer9: 550-562 doi: 10.1038/nrc2664
23	Engelman JA, Luo J, Cantley LC(2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet7: 606-619 doi: 10.1038/nrg1879
24	Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab17: 113-124 doi: 10.1016/j.cmet.2012.12.001
25	Fets L, Anastasiou D(2013) p73 keeps metabolic control in the family. Nat Cell Biol15: 891-893 doi: 10.1038/ncb2810
26	Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature458: 762-765 doi: 10.1038/nature07823
27	Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC, Anastasiou D, Ito K, Sasaki AT, Rameh L (2012) Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell149: 49-62 doi: 10.1016/j.cell.2012.02.030
28	Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA(2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev20: 1218-1249 doi: 10.1101/gad.1415606
29	Hong X, Song R, Song H, Zheng T, Wang J, Liang Y, Qi S, Lu Z, Song X, Jiang H (2013) PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut. 0:gutjnl-2013-305302v1-gutjnl-2013-305302
30	Hsu PP, Sabatini DM(2008) Cancer cell metabolism: Warburg and beyond. Cell134: 703-707 doi: 10.1016/j.cell.2008.08.021
31	Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z(2010) Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA107: 7455-7460 doi: 10.1073/pnas.1001006107
32	Huang W, Choi W, Chen Y, Zhang Q, Deng H, He W, Shi Y(2013) A proposed role for glutamine in cancer cell growth through acid resistance. Cell Res23: 724-727 doi: 10.1038/cr.2013.15
33	Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, Yang X(2011) p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol13: 310-316 doi: 10.1038/ncb2172
34	Jiang P, Du W, Mancuso A, Wellen KE, Yang X(2013a) Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature493: 689-693 doi: 10.1038/nature11776
35	Jiang P, Du W, Yang X(2013b) A critical role of glucose-6-phosphate dehydrogenase in TAp73-mediated cell proliferation. Cell Cycle12: 3720-3726 doi: 10.4161/cc.27267
36	Jiang P, Du W, Yang X(2013c) p53 and regulation of tumor metabolism. J Carcinog12: 21 doi: 10.4103/1477-3163.122760
37	Jones NP, Schulze A(2012) Targeting cancer metabolism—aiming at a tumour’s sweet-spot. Drug Discov Today17: 232-241 doi: 10.1016/j.drudis.2011.12.017
38	Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB(2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell18: 283-293 doi: 10.1016/j.molcel.2005.03.027
39	Kletzien RF, Harris PK, Foellmi LA(1994) Glucose-6-phosphate dehydrogenase: a “housekeeping” enzyme subject to tissuespeciflc regulation by hormones, nutrients, and oxidant stress. FASEB J8: 174-181
40	Kohan AB, Talukdar I, Walsh CM, Salati LM(2009) A role for AMPK in the inhibition of glucose-6-phosphate dehydrogenase by polyunsaturated fatty acids. BiochemBiophys Res Commun388: 117-121 doi: 10.1016/j.bbrc.2009.07.130
41	Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D(2005) Glycolytic enzymes can modulate cellular life span. Cancer Res65: 177-185
42	Koppenol WH, Bounds PL, Dang CV(2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer11: 325-337 doi: 10.1038/nrc3038
43	Kroemer G, Pouyssegur J(2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell13: 472-482 doi: 10.1016/j.ccr.2008.05.005
44	Kuo W, Lin J, Tang TK(2000) Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int J Cancer85: 857-864 doi: 10.1002/(SICI)1097-0215(20000315)85:6<857::AID-IJC20>3.0.CO;2-U
45	Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, Alken P, Coy JF(2008) Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer122: 2422-2428 doi: 10.1002/ijc.23403
46	Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J(2007) Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med13: 189-197 doi: 10.1038/nm1545
47	Liang Y, Liu J, Feng Z(2013) The regulation of cellular metabolism by tumor suppressor p53. Cell Biosci3: 9 doi: 10.1186/2045-3701-3-9
48	Longo L, Vanegas OC, Patel M, Rosti V, Li H, Waka J, Merghoub T, Pandolfl PP, Notaro R, Manova K (2002) Maternally transmitted severe glucose 6-phosphate dehydrogenase deflciency is an embryonic lethal. EMBO J21: 4229-4239 doi: 10.1093/emboj/cdf426
49	Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol27: 441-464 doi: 10.1146/annurev-cellbio-092910-154237
50	Maehama T, Dixon JE(1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem273: 13375-13378 doi: 10.1074/jbc.273.22.13375
51	Manganelli G, Masullo U, Passarelli S, Filosa S(2013) Glucose-6-phosphate dehydrogenase deflciency: disadvantages and possible beneflts. Cardiovasc Hematol Disord Drug Targets13: 73-82 doi: 10.2174/1871529X11313010008
52	Manning BD, Cantley LC(2007) AKT/PKB signaling: navigating downstream. Cell129: 1261-1274 doi: 10.1016/j.cell.2007.06.009
53	Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM(2006) p53 regulates mitochondrial respiration. Science312: 1650-1653 doi: 10.1126/science.1126863
54	Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL (2008) An integrated genomic analysis of human glioblastoma multiforme. Science321: 1807-1812 doi: 10.1126/science.1164382
55	Quade BJ, Wang TY, Sornberger K, Dal Cin P, Mutter GL, Morton CC(2004) Molecular pathogenesis of uterine smooth muscle tumors fromtranscriptional proflling. Genes Chromosom Cancer40: 97-108 doi: 10.1002/gcc.20018
56	Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM (2002) The use of molecular proflling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med346: 1937-1947 doi: 10.1056/NEJMoa012914
57	Ruflni A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A, Federici M, Dinsdale D, Knight RA, Melino G (2012) TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev26: 2009-2014 doi: 10.1101/gad.197640.112
58	Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN(2011) Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer117: 2926-2938 doi: 10.1002/cncr.25868
59	Schulz E, Anter E, Zou MH, Keaney JF Jr (2005) Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation111: 3473-3480 doi: 10.1161/CIRCULATIONAHA.105.546812
60	Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E(2004) The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res64: 2627-2633 doi: 10.1158/0008-5472.CAN-03-0846
61	Shaw RJ, Cantley LC(2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature441: 424-430 doi: 10.1038/nature04869
62	Shen L, Sun X, Fu Z, Yang G, Li J, Yao L(2012) The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy. Clin Cancer Res18: 1561-1567 doi: 10.1158/1078-0432.CCR-11-3040
63	Simpson L, Parsons R(2001) PTEN: life as a tumor suppressor. Exp Cell Res264: 29-41 doi: 10.1006/excr.2000.5130
64	Stahmann N, Woods A, Carling D, Heller R(2006) Thrombin activates AMP-activated protein kinase in endothelial cells via a pathway involving Ca2+/calmodulin-dependent protein kinase kinase beta. Mol Cell Biol26: 5933-5945 doi: 10.1128/MCB.00383-06
65	Stanton RC(2012) Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life64: 362-369 doi: 10.1002/iub.1017
66	Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT, Franklin WA (2005) Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol167: 1763-1775 doi: 10.1016/S0002-9440(10)61257-6
67	Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH (2007) Selection ofDDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics8: 140 doi: 10.1186/1471-2164-8-140
68	Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JY(2006) Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation114: 2655-2662 doi: 10.1161/CIRCULATIONAHA.106.630194
69	Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y (2010) Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA107: 7461-7466 doi: 10.1073/pnas.1002459107
70	Tian WN, Braunstein LD, Pang J, Stuhlmeier KM, Xi QC, Tian X, Stanton RC(1998) Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem273: 10609-10617 doi: 10.1074/jbc.273.17.10609
71	Towler MC, Hardie DG(2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res100: 328-341 doi: 10.1161/01.RES.0000256090.42690.05
72	Vander Heiden MG, Cantley LC, Thompson CB(2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science324: 1029-1033 doi: 10.1126/science.1160809
73	Varshney R, Dwarakanath B, Jain V(2005) Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int J Radiat Biol81: 397-408 doi: 10.1080/09553000500148590
74	Wagle A, Jivraj S, Garlock GL, Stapleton SR(1998) Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is rapamycin-sensitive and requires phosphatidylinositol 3-kinase. J Biol Chem273: 14968-14974 doi: 10.1074/jbc.273.24.14968
75	Warburg O(1956) On the origin of cancer cells. Science123: 309-314 doi: 10.1126/science.123.3191.309
76	Warburg O, Posener K, Negelein E(1924) Ueber den Stoffwechsel der Tumoren. Biochem Z152: 319-344
77	Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell17: 225-234 doi: 10.1016/j.ccr.2010.01.020
78	Ward PS, Cross JR, Lu C, Weigert O, Abel-Wahab O, Levine RL, Weinstock DM, Sharp KA, Thompson CB(2012) Identiflcation of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene31: 2491-2498 doi: 10.1038/onc.2011.416
79	Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA105: 18782-18787 doi: 10.1073/pnas.0810199105
80	Wood T(1986) Physiological functions of the pentose phosphate pathway. Cell Biochem Funct4: 241-247 doi: 10.1002/cbf.290040403
81	Xu Y, Osborne BW, Stanton RC(2005) Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol289: F1040-F1047 doi: 10.1152/ajprenal.00076.2005
82	Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med360: 765-773 doi: 10.1056/NEJMoa0808710
83	Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell149: 656-670 doi: 10.1016/j.cell.2012.01.058
84	Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y(2007) Deflciency in glutamine but not glucose induces MYCdependent apoptosis in human cells. J Cell Biol178: 93-105 doi: 10.1083/jcb.200703099
85	Zhang Z, Apse K, Pang J, Stanton RC(2000) High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem275: 40042-40047 doi: 10.1074/jbc.M007505200
86	Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science324: 261-265 doi: 10.1126/science.1170944
87	Zmijewski JW, Banerjee S, Bae H, Friggeri A, Lazarowski ER, Abraham E(2010) Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase. J Biol Chem285: 33154-33164 doi: 10.1074/jbc.M110.143685
88	Zoncu R, Efeyan A, Sabatini DM(2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol12: 21-35 doi: 10.1038/nrm3025
89	Zou MH, Hou XY, Shi CM, Kirkpatick S, Liu F, Goldman MH, Cohen RA(2003) Activation of 5’-AMP-activated kinase is mediated through c-Src and phosphoinositide 3-kinase activity during hypoxia-reoxygenation of bovine aortic endothelial cells. Role of peroxynitrite. J Biol Chem278: 34003-34010 doi: 10.1074/jbc.M300215200

[1]	Mona Teng, Stanley Zhou, Changmeng Cai, Mathieu Lupien, Housheng Hansen He. Pioneer of prostate cancer: past, present and the future of FOXA1[J]. Protein Cell, 2021, 12(1): 29-38.
[2]	Henry Y. Jiang, Sara Najmeh, Guy Martel, Elyse MacFadden-Murphy, Raquel Farias, Paul Savage, Arielle Leone, Lucie Roussel, Jonathan Cools-Lartigue, Stephen Gowing, Julie Berube, Betty Giannias, France Bourdeau, Carlos H. F. Chan, Jonathan D. Spicer, Rebecca McClure, Morag Park, Simon Rousseau, Lorenzo E. Ferri. Activation of the pattern recognition receptor NOD1 augments colon cancer metastasis[J]. Protein Cell, 2020, 11(3): 187-201.
[3]	Ruyi Xu, Yi Li, Yang Liu, Jianwei Qu, Wen Cao, Enfan Zhang, Jingsong He, Zhen Cai. How are MCPIP1 and cytokines mutually regulated in cancer-related immunity?[J]. Protein Cell, 2020, 11(12): 881-893.
[4]	Weiwei Jiang, Fangfang Cai, Huangru Xu, Yanyan Lu, Jia Chen, Jia Liu, Nini Cao, Xiangyu Zhang, Xiao Chen, Qilai Huang, Hongqin Zhuang, Zi-Chun Hua. Extracellular signal regulated kinase 5 promotes cell migration, invasion and lung metastasis in a FAK-dependent manner[J]. Protein Cell, 2020, 11(11): 825-845.
[5]	Fenjie Li, Junjun Ding. Sialylation is involved in cell fate decision during development, reprogramming and cancer progression[J]. Protein Cell, 2019, 10(8): 550-565.
[6]	Wei Shao, Shasha Li, Lu Li, Kequan Lin, Xinhong Liu, Haiyan Wang, Huili Wang, Dong Wang. Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun[J]. Protein Cell, 2019, 10(3): 161-177.
[7]	Boyi Zhang, Fei Chen, Qixia Xu, Liu Han, Jiaqian Xu, Libin Gao, Xiaochen Sun, Yiwen Li, Yan Li, Min Qian, Yu Sun. Revisiting ovarian cancer microenvironment: a friend or a foe?[J]. Protein Cell, 2018, 9(8): 674-692.
[8]	Yelei Guo, Kaichao Feng, Yao Wang, Weidong Han. Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment[J]. Protein Cell, 2018, 9(6): 516-526.
[9]	Jia Yang, Jun Yu. The association of diet, gut microbiota and colorectal cancer: what we eat may imply what we get[J]. Protein Cell, 2018, 9(5): 474-487.
[10]	Xiao-xiao Xu, Han Wan, Li Nie, Tong Shao, Li-xin Xiang, Jian-zhong Shao. RIG-I: a multifunctional protein beyond a pattern recognition receptor[J]. Protein Cell, 2018, 9(3): 246-253.
[11]	Nicole M. Anderson, Patrick Mucka, Joseph G. Kern, Hui Feng. The emerging role and targetability of the TCA cycle in cancer metabolism[J]. Protein Cell, 2018, 9(2): 216-237.
[12]	John M. Dean, Irfan J. Lodhi. Structural and functional roles of ether lipids[J]. Protein Cell, 2018, 9(2): 196-206.
[13]	Yanjing Song, Chuan Tong, Yao Wang, Yunhe Gao, Hanren Dai, Yelei Guo, Xudong Zhao, Yi Wang, Zizheng Wang, Weidong Han, Lin Chen. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo[J]. Protein Cell, 2018, 9(10): 867-878.
[14]	Xiaowei Chen, Zhen Fan, Warren McGee, Mengmeng Chen, Ruirui Kong, Pushuai Wen, Tengfei Xiao, Xiaomin Chen, Jianghong Liu, Li Zhu, Runsheng Chen, Jane Y. Wu. TDP-43 regulates cancer-associated microRNAs[J]. Protein Cell, 2018, 9(10): 848-866.
[15]	Kaichao Feng, Yang Liu, Yelei Guo, Jingdan Qiu, Zhiqiang Wu, Hanren Dai, Qingming Yang, Yao Wang, Weidong Han. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers[J]. Protein Cell, 2018, 9(10): 838-847.

Viewed

Full text

Abstract

Cited

Shared

Discussed